- Home
- CLVT vs IMVT Comparison
CLVT vs IMVT Comparison
Compare CLVT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- IMVT
- Stock Information
- Founded
- CLVT 2016
- IMVT 2018
- Country
- CLVT United Kingdom
- IMVT United States
- Employees
- CLVT N/A
- IMVT N/A
- Industry
- CLVT EDP Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLVT Technology
- IMVT Health Care
- Exchange
- CLVT Nasdaq
- IMVT Nasdaq
- Market Cap
- CLVT 2.8B
- IMVT 2.7B
- IPO Year
- CLVT N/A
- IMVT N/A
- Fundamental
- Price
- CLVT $4.51
- IMVT $15.24
- Analyst Decision
- CLVT Hold
- IMVT Buy
- Analyst Count
- CLVT 4
- IMVT 11
- Target Price
- CLVT $4.83
- IMVT $35.88
- AVG Volume (30 Days)
- CLVT 4.9M
- IMVT 1.2M
- Earning Date
- CLVT 07-30-2025
- IMVT 08-11-2025
- Dividend Yield
- CLVT N/A
- IMVT N/A
- EPS Growth
- CLVT N/A
- IMVT N/A
- EPS
- CLVT N/A
- IMVT N/A
- Revenue
- CLVT $2,500,300,000.00
- IMVT N/A
- Revenue This Year
- CLVT N/A
- IMVT N/A
- Revenue Next Year
- CLVT $0.21
- IMVT N/A
- P/E Ratio
- CLVT N/A
- IMVT N/A
- Revenue Growth
- CLVT N/A
- IMVT N/A
- 52 Week Low
- CLVT $3.04
- IMVT $12.72
- 52 Week High
- CLVT $7.15
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- CLVT 64.16
- IMVT 43.58
- Support Level
- CLVT $4.28
- IMVT $14.50
- Resistance Level
- CLVT $4.49
- IMVT $15.52
- Average True Range (ATR)
- CLVT 0.15
- IMVT 0.69
- MACD
- CLVT 0.07
- IMVT -0.06
- Stochastic Oscillator
- CLVT 94.97
- IMVT 41.16
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.